Menomune A/C/Y/W-135 Side Effects

Generic name: meningococcal polysaccharide vaccine

Medically reviewed by Drugs.com. Last updated on Jul 28, 2024.

Note: This document provides detailed information about Menomune A/C/Y/W-135 Side Effects associated with meningococcal polysaccharide vaccine. Some dosage forms listed on this page may not apply specifically to the brand name Menomune A/C/Y/W-135.

Applies to meningococcal polysaccharide vaccine: intramuscular kit, intramuscular solution, intramuscular suspension.

Other side effects

Some side effects of meningococcal polysaccharide vaccine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
• chills
• diarrhea
• fever
• headache
• joint pain
• muscle pain
• vomiting

Serious side effects

Along with its needed effects, meningococcal polysaccharide vaccine (the active ingredient contained in Menomune A/C/Y/W-135) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking meningococcal polysaccharide vaccine:

Incidence not known

• chest tightness
• cough
• difficulty swallowing
• dizziness
• fainting
• fast heartbeat
• hives, itching, skin rash
• inability to move arms and legs
• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
• sudden numbness and weakness in the arms and legs
• trouble breathing
• unusual tiredness or weakness

For healthcare professionals

Applies to meningococcal polysaccharide vaccine: subcutaneous powder for injection.

General

The most common adverse events were injection site pain, headache, irritability, and diarrhea.^[Ref]

Local

• Very common (10% or more): Injection site pain (48.1%), injection site redness (16%), injection site induration (11%), injection site tenderness
• Common (1% to 10%): Injection site swelling, injection site hematoma
• Uncommon (0.1% to 1%): Injection site reaction
• Rare (less than 0.1%): Severe local reactions
• Postmarketing reports: Extensive limb swelling at the injection site (frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb)^[Ref]

Nervous system

• Very common (10% or more): Headache (41.8%), drowsiness (11.2%)
• Uncommon (0.1% to 1%): Hypoesthesia, dizziness
• Very rare (less than 0.01%): Somnolence, neurological reactions
• Postmarketing reports: Vasovagal syncope, paresthesia, Guillain-Barre syndrome^[Ref]

Other

• Very common (10% or more): Fatigue (32.3%), malaise (22.3%), fever
• Common (1% to 10%): Chills, febrile reactions (>38C)
• Postmarketing reports: Asthenia, influenza-like symptoms^[Ref]

Psychiatric

• Very common (10% or more): Irritability (12.2%)
• Uncommon (0.1% to 1%): Insomnia, crying^[Ref]

Musculoskeletal

• Very common (10% or more): Arthralgia (16%)
• Uncommon (0.1% to 1%): Myalgia, pain in extremity
• Postmarketing reports: Musculoskeletal stiffness^[Ref]

Metabolic

• Very common (10% or more): Appetite lost
• Common (1% to 10%): Anorexia
• Postmarketing reports: Decreased appetite^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (14%)
• Common (1% to 10%): Vomiting, nausea^[Ref]

Dermatologic

• Common (1% to 10%): Rash
• Uncommon (0.1% to 1%): Pruritus
• Rare (less than 0.1%): Urticaria, angioedema
• Postmarketing reports: Angioneurotic edema^[Ref]

Hematologic

• Very common (10% or more): Local axillary lymphadenopathy^[Ref]

Hypersensitivity

• Postmarketing reports: Hypersensitivity (such as rash, urticaria, pruritus, dyspnea, angioedema), allergic reactions (including anaphylactic and anaphylactoid reactions)^[Ref]

Respiratory

• Uncommon (0.1% to 1%): Upper respiratory tract illness
• Rare (less than 0.1%): Wheeze^[Ref]

Renal

• Postmarketing reports: IgA nephropathy^[Ref]

Further information

Menomune A/C/Y/W-135 side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer